Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial

BE0000065ProteinHumansDLAT

The pyruvate dehydrogenase (PDH) complex, catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It is acted on by 3 drugs in DrugBank.

Gene name
DLAT
UniProtKB entry
P10515Swiss-Prot
Cellular location
Mitochondrion matrix
Residues / weight
647 residues · 68,996 Da
Also known as
2.3.1.12 · 70 kDa mitochondrial autoantigen of primary biliary cirrhosis · Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex · DLTA · M2 antigen complex 70 kDa subunit

Resolves to

Protein
UniProtP10515UniProt nameODP2_HUMAN
Gene
HGNCHGNC:2896NCBI Gene1737GenBank35360GeneCardsDLAT
Pharmacology
KEGGhsa:1737
Structure
PDB1FYCPDB1Y8NPDB1Y8O
Drugs

What you can answer from here — as of September 07, 2019

3DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
1GO termFunction, process and component, as structured annotations
Sign in
3Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
17+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In